Fujifilm Medical Systems USA has secured premarket approval (PMA) from the US Food and Drug Administration (FDA) for its Digital Breast Tomosynthesis (DBT) option of ASPIRE Cristalle system.

DBT has been developed as an optional software upgrade for the digital mammography ASPIRE Cristalle FFDM system.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Designed to optimise patient dose and improve image quality, the ASPIRE Cristalle FFDM system with DBT utilises a combination of hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow.

The software option enables the x-ray tube to move in an arc around the breast, obtain a series of low-dose image slices at different angles and generate a three-dimensional view.

Fujifilm Medical Systems Strategic Marketing, Digital Radiography and Women’s Health director Rob Fabrizio said: “The unique dose savings and patient comfort innovations already available in the ASPIRE Cristalle FFDM system are now coupled with the new 3D imaging capabilities, an exciting advancement that US providers have long been waiting for in their fight for early detection of breast cancer.”

"The software option enables the x-ray tube to move in an arc around the breast, obtain a series of low-dose image slices at different angles and generate a three-dimensional view."

The images obtained through the device are reconstructed into a series of high-resolution 1mm slices and are displayed individually or dynamically in a cine mode, which avoids overlapping breast structures and helps in easy detection of lesions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The combination of ASPIRE Cristalle FFDM system with DBT is expected to offer diagnostic accuracy and decrease the recall rates for non-cancer cases.

Available in Europe, Asia and Latin America since May 2013, the DBT upgrade option will now be accessible for use across the US.

Image: Fujifilm ASPIRE Cristalle mammography system. Photo: courtesy of Fujifilm.